|
市場調查報告書
更好的癌症疫苗研發
Building Better Cancer Vaccines: The Progress and Promise of R&D
|
本報告已在2011年12月21日停止出版。
手術或化學療法、放射線療法等標準癌症治療方法的臨床效果多半都有其侷限，相對地，以提昇人體本身免疫力以阻止癌症惡化的癌症疫苗在未來有龐大的市場機會。
專門於醫療產業相關廣泛調查的美國市調公司Decision Resources Inc. （總公司：美國Massachusetts洲），針對更好的癌症疫苗研發進行調查分析，並系統整理調查結果後出版報告書"Building Better Cancer Vaccines: The Progress and Promise of R&D" 。
本報告書內容包括：抑制癌細胞擴散之免疫系統的角色、癌症疫苗概要及策略、癌症疫苗功效提昇、未來發展預測等。內容綱要摘記如下：
實施概要
癌症疫苗：新武器
腫瘤免疫學
癌症疫苗概要
- 預防用癌症疫苗
- Merck的Gardasil
- GlaxoSmithKline的Cervarix
- 治療用癌症疫苗
癌症疫苗策略
- 細胞疫苗
- 自體全腫瘤細胞疫苗
- 原位全腫瘤細胞疫苗
- 基因重組全腫瘤細胞疫苗
- 樹枝狀細胞疫苗
- 蛋白疫苗
- 載體疫苗
為提高癌症疫苗功效之佐藥使用
未來評估事項
表
- 隨著癌細胞擴散需要的傳染病治療藥
- 治療用癌症疫苗策略的優點及缺點
- 開發中的癌症疫苗：2007年
- 開發中的癌症疫苗佐藥：2007年
- 癌症疫苗國際財團
圖
Abstract
Introduction
Cancer vaccines are the newest weapon in the battle against cancer. Vaccines
promise to boost the body' s natural abilities to halt the progression of the
disease. Although standard cancer treatments such as surgery, chemotherapy,
and radiation have improved the clinical outcomes of many patients, these
treatments have limitations and toxicities that can deter their utility. Thus,
there is substantial market opportunity for cancer vaccines.
Get the Answers You Need to Shape Your Strategy
- Cancer vaccination trains the patient' s own immune system to specifi cally
recognize and destroy tumor cells without harming normal cells. What
requirements must a cancer vaccine satisfy to achieve signifi cant clinical
response? Which patients are ideal candidates for cancer vaccination? Are
clinical trial data masking the true effi cacy potential of cancer vaccines?
- Manufacturers of cancer vaccines have faced considerable regulatory and
production challenges, particularly developers of personalized vaccines that
require the use of the patient' s own tissues. What are some of the diffi
culties faced by manufacturers of cancer vaccines? Which key development
questions need to be considered before a developer pursues a particular
vaccination strategy?
- Because of their ability to boost the body' s immune response to the
vaccine, cancer vaccine adjuvants have become critical components of any
cancer vaccine product. Companies in this arena should try to investigate ways
to incorporate adjuvants into their research. What are the key adjuvants now
in development for cancer vaccines, and which agent is showing the greatest
promise?
Scope
- Tumor immunology: Overview of the role that the immune system plays in the
prevention of cancer development.
- The cancer vaccine concept: The ability of cancer vaccines to train the
patient' s immune system to recognize and destroy tumor cells without harming
normal cells.
- Cancer vaccine strategies: Description and examples of cell-based,
protein-based, and vector-based vaccines.
- Improving cancer vaccine effi cacy: The use of adjuvants and their role in
boosting cancer vaccine effi cacy.
- Future perspectives: Key challenges faced by developers of cancer vaccines.
Table of Contents
- Executive Summary
- Strategic Considerations
- Stakeholder Implications
- Cancer Vaccines: A New Weapon
- Tumor Immunology
- The Cancer Vaccine Concept
- Preventive Cancer Vaccines
- Merck' s Gardasil
- GlaxoSmithKline' s Cervarix
- Therapeutic Cancer Vaccines
- Cancer Vaccine Strategies
- Cell-Based Vaccines
- Autologous Whole Tumor Cell Vaccines
- Allogeneic Whole Tumor Cell Vaccines
- Genetically Modifi ed Whole Tumor Cell Vaccines
- Dendritic Cell Vaccines
- Protein-Based Vaccines
- Peptide-Based Vaccines
- Heat-Shock-Protein-Based Vaccines
- Vector-Based Vaccines
- Virus-Based Vaccines
- Bacteria-Based Vaccines
- DNA-Based Vaccines
- Use of Adjuvants to Improve Cancer Vaccine Effi cacy
- Future Considerations
- Addressing Key Development Questions
- The Need for Collaborations
Tables:
- 1. Infectious Agents Associated with Cancer Development
- 2. Advantages and Disadvantages of Therapeutic Cancer Vaccine Strategies
- 3. Select Cancer Vaccines in Development, 2007
- 4. Select Cancer Vaccine Adjuvants in Development, 2007
- 5. The Cancer Vaccine Consortium
Figures:
- 1. Number of Cancer Vaccines by Phase of Clinical Development, 2007
|
